|12th February 2021||Advisors Llc Orbimed||104,050||Grant/award etc.||$13.00||$1,352,650.00|
|12th February 2021||Advisors Llc Orbimed||420,299||Grant/award etc.||$13.00||$5,463,887.00|
|9th February 2021||Advisors Llc Orbimed||1,989,723||Conversion of derivative||$0.00|
|9th February 2021||Advisors Llc Orbimed||1,326,481||Conversion of derivative||$0.00|
|9th February 2021||Advisors Llc Orbimed||190,000||Open or private purchase||$17.00||$3,230,000.00|
|9th February 2021||Advisors Llc Orbimed||285,000||Open or private purchase||$17.00||$4,845,000.00|
|22nd January 2021||Advisors Llc Orbimed||13,822,463||Disposition due to a tender of shares in a change of control transaction||$0.00|
|7th January 2021||Advisors Llc Orbimed||2,000,000||Open or private sale||$3.50||$7,000,000.00|
|28th December 2020||Advisors Llc Orbimed||600,000||Open or private sale||$14.25||$8,550,000.00|
|8th December 2020||Venture Investments, Llc Alexandria||699,412||Conversion of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
NextCure, Inc. is a clinical-stage biopharmaceutical company. It is developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function.